Literature DB >> 551151

Transcutaneous oxygen (tcPO2) measurements as an aid to fluid therapy in necrotizing enterocolitis.

W L Buntain, E Conner, J Emrico, G Cassady.   

Abstract

Impaired peripheral perfusion is a major problem in necrotizing enterocolitis with delayed recognition and definite documentation being primary factors. While blood pressure and other clinical measurements may improperly estimate the severity of the problem, changes in transcutaneous oxygen measurements and their relationship to arterial oxygen (the tcPO2/PaO2 ratio) potentially afford a sensitive measurement of peripheral perfusion. Experience in our unit confirms a close relationship between tcPO2/ and PaO2 being 0.97 +/- 0.04 (SE). Ten infants with birth weights of 640 to 1380 g, who subsequently developed necrotizing enterocolitis, had strikingly lower ratios initially (0.00, 0.00, 0.00, 0.17, 0.21, 0.43, 0.44, 0.48, and 0.56). Use of the tcPO2/PaO2 ratio to monitor fluid therapy was related to outcome, suggesting that this ratio is important in managing necrotizing enterocolitis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 551151     DOI: 10.1016/s0022-3468(79)80254-7

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  Fundamentals of infant anaesthesia.

Authors:  C F Ward
Journal:  Can Anaesth Soc J       Date:  1984-05

2.  An update on pediatric monitoring.

Authors:  C F Ward
Journal:  J Clin Monit       Date:  1985-07

Review 3.  Necrotizing enterocolitis: treatment based on staging criteria.

Authors:  M C Walsh; R M Kliegman
Journal:  Pediatr Clin North Am       Date:  1986-02       Impact factor: 3.278

Review 4.  Optimizing Nutritional Strategies to Prevent Necrotizing Enterocolitis and Growth Failure after Bowel Resection.

Authors:  Laura Moschino; Miriam Duci; Francesco Fascetti Leon; Luca Bonadies; Elena Priante; Eugenio Baraldi; Giovanna Verlato
Journal:  Nutrients       Date:  2021-01-24       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.